While EGFR-TKIs might be applied to C-SCLC harboring EGFR mutations, the limited data available makes it difficult to precisely determine their efficacy, which may also be less pronounced in SCLC or C-SCLC than in NSCLC. Here, EGFR is linked to small cell lung carcinoma.